The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

Expansion into the supply chain side of the drug industry is ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...

Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions ...